REGENXBIO Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Stockholders held on June 1, 2016. The filing details the results of shareholder votes regarding director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 26,338,329 shares entitled to vote, 17,437,412 shares (approximately 66.20%) were represented, constituting a quorum.
Proposal 1: Election of Directors
Stockholders elected two Class I directors for a three-year term until the 2019 annual meeting.
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Allan M. Fox | 13,438,632 | 3,378,643 | 620,137 |
| Camille Samuels | 13,521,616 | 3,295,659 | 620,137 |
Proposal 2: Ratification of Auditor
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
| Votes For | Votes Against | Votes Abstaining | Broker Non-Votes |
|---|---|---|---|
| 17,435,282 | 2,130 | 0 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For additional context, the filing references the definitive proxy statement on Schedule 14A filed on April 18, 2016.
Key Facts for Investor Verification
- Quorum was established with 66.20% of eligible shares represented.
- Both director nominees (Allan M. Fox and Camille Samuels) received significant support, though over 3.3 million votes were withheld for each.
- The ratification of PricewaterhouseCoopers LLP was overwhelmingly approved with only 2,130 votes against.
- Financial performance data is not included in this specific 8-K filing.